Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:IMPL

Impel Pharmaceuticals (IMPL) Stock Price, News & Analysis

Impel Pharmaceuticals logo

About Impel Pharmaceuticals Stock (NASDAQ:IMPL)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.04
$0.84
52-Week Range
N/A
Volume
720,000 shs
Average Volume
682,655 shs
Market Capitalization
$956 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive IMPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IMPL Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.tc pixel
Impel Pharmaceuticals Inc. (IMPLQ)
See More Headlines

IMPL Stock Analysis - Frequently Asked Questions

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) posted its quarterly earnings data on Monday, November, 15th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.42. The business had revenue of $0.09 million for the quarter.
Read the conference call transcript
.

Impel Pharmaceuticals (IMPL) raised $80 million in an initial public offering on Friday, April 23rd 2021. The company issued 5,300,000 shares at $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Impel Pharmaceuticals investors own include Athenex (ATNX), NIO (NIO), KLX Energy Services (KLXE), American Airlines Group (AAL), Bolt Biotherapeutics (BOLT), Moderna (MRNA) and Novavax (NVAX).

Company Calendar

Last Earnings
11/15/2021
Today
8/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMPL
CIK
1445499
Fax
N/A
Employees
160
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$106.31 million
Net Margins
-353.93%
Pretax Margin
-353.93%
Return on Equity
N/A
Return on Assets
-127.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.19
Quick Ratio
0.13

Sales & Book Value

Annual Sales
$20.99 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.86) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
23,900,000
Free Float
22,418,000
Market Cap
$956 thousand
Optionable
Not Optionable
Beta
1.17
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:IMPL) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners